Date: 2015-03-04
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 4, 2015, Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, announced that it has strengthened its senior management team with the appointment of Dr. Rafael Amado, as Chief Medical Officer, and Adrian (Ad) Rawcliffe, as Chief Financial Officer. Both appointments are effective from 16 March. Dr. Amado will lead Adaptimmune’s clinical strategy and assume responsibility for the company’s clinical trials across the US and Europe under its strategic collaboration with GSK. He will also lead the development of the company’s pipeline of wholly-owned research programs. Prior to joining Adaptimmune, Dr. Amado served as Senior Vice President and Head of Oncology R&D at GSK, where he was responsible for integrating oncology global R&D activities, from drug target identification to clinical development and registration. Dr. Amado joined GSK in 2008 as Vice President of Clinical Development, and served in positions of increasing responsibility, including Senior Vice President and Head of Oncology Clinical Development. He oversaw the development and registration globally of over fifteen novel indications across six products and led the development of a pipeline of products in novel areas of cancer biology. Prior to joining GSK, Dr. Amado was Executive Director of Therapeutic Oncology at Amgen where he was responsible for development activities of several assets. An area of his interest is biological characterization of tumors for patient selection, which he applied to targeted drug development with anti-EGFR agents in colorectal cancer, as well as the development of drug combinations. He trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty until joining Amgen in 2003. Mr. Rawcliffe will lead Adaptimmune’s financial management and operations functions including compliance and risk management. He joins from GSK where he was Senior Vice President, Finance of its North American Pharmaceuticals business. Prior to this, Mr. Rawcliffe held a variety of senior finance and business development roles at GSK, including Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all Pharmaceuticals R&D business development and finance activities, and Managing Partner and President of SR One Ltd, GSK’s venture-capital business. Mr. Rawcliffe joined GSK in 1998 and holds a BSc degree in Natural Sciences from the University of Durham, UK. He qualified as a Chartered Accountant with Coopers & Lybrand.
Financial terms:
Latest news:
